Pharmascience Canada expands its portfolio with a treatment for Parkinson’s disease patients

Montreal, 5 March 2025 – Pharmascience Canada is pleased to announce the lauch of ^Prpms-LEVODOPA-CARBIDOPA (levodopa and carbidopa tablets), a treatment used to treat the symptoms of Parkinson’s disease in adults. ¹ 

Indications and other details related to ^Prpms-LEVODOPA-CARBIDOPA:  

^Prpms-LEVODOPA-CARBIDOPA is indicated for the treatment of Parkinson’s disease. It is thought ² that the symptoms of this disease are caused by a lack of dopamine, a natural substance produced by certain brain cells. Dopamine plays a role in relaying messages to specific regions of the brain that control muscle movement. Difficulty in movement results when too little dopamine is produced.¹

^Prpms-LEVODOPA-CARBIDOPA contains two ingredients:

• Levodopa: this acts to replenish dopamine in the brain ¹
• Carbidopa: ensures that enough levodopa gets to the brain where it is needed. ¹

In many patients, this treatment reduces the symptoms of Parkinson’s disease. ¹

The most common side effects during treatment with ^Prpms-LEVODOPA-CARBIDOPA (levodopa and carbidopa tablets) are dyskinesias, including choreiform, dystonic, and other involuntary movements and nausea. It is contraindicated in patients who are hypersensitive to this drug or to any ingredient. ¹

^Prpms-LEVODOPA-CARBIDOPA is available in oral form following dosage forms: tablets of 100 mg / 25 mg (yellow), 100 mg / 10 mg (blue) and 250 mg / 25 mg (blue). ¹

“Providing patients access to critical medications is of utmost importance. With the launch of ^Prpms-LEVODOPA CARBIDOPA, we continue to provide medications that have an important impact on the lives of Canadians” – said Mike Dutton, Vice President and General Manager, Pharmascience Canada.

About Pharmascience inc.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,600 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 52^nd among Canada’s top 100 Research and Development (R&D) investors in 2023, with $40-50 million invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in employees and young people. Through various programs and initiatives, the company is dedicated to supporting their personal development and life. In 2024, the company was awarded Great Place to Work certification for the third consecutive year, and also made the Top 50 best places to work in Canada by Great Place to Work Canada for the category of companies with over 1,000 employees.

For more information about the product, such as contraindications, precautions, adverse effects, drug interactions, dosage and clinical usage conditions, please consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00076240.PDF. This document is also available through our medical department at [email protected] or by calling us at +1 (888) 550-6060.

We encourage patients to consult their doctor for more information to ensure this treatment right choice for them. Always read and follow the label. This product may not be right for you.

¹ Product monograph of ^Prpms-LEVODOPA-CARBIDOPA  : https://pdf.hres.ca/dpd_pm/00076240.PDF 

²Parkinson disease 101 – Parkinson’s Association of Alberta